Unit AP707 Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face Assignment Brief
| Qualification | Qualifi Level 7 Diploma in Clinical Aesthetic Practice (610/7007/5)
Qualifi Level 7 Certificate in Clinical Aesthetic Procedures: Botulinum Toxin Injections (610/7010/5) |
| Unit Reference Number | Y/651/9196 |
| Unit Code | AP707 |
| Unit Title | Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face |
| RQF Level : | 7 |
| Number of Credits | 15 |
| Total Qualification Time (TQT) | 150 hours |
| Guided Learning Hours (GLH) | 75 hours |
Learning Outcomes, and Assessment Criteria
| Learning Outcomes. To achieve this unit a learner must be able to: | Assessment Criteria. Assessment of these outcomes demonstrates a learner can: | NOS/KSBs | ||
| LO1 | Adhere to legal, ethical and professional standards for botulinum toxin procedures
|
1.1 | Obtain and discuss the client’s consultation outcomes and prescription for the botulinum toxin type A procedure from the regulated independent prescriber to include:
• legal, regulatory and organisational requirements • client procedure plan and areas to be treated • advice, support and guidance • emergency plan • medicine management policy • pain management strategy |
PC1, PC2
KU1, KU2, KU3 KU18 KU19
|
| 1.2 |
Describe the types, composition and pharmacological effects of chemical compounds in botulinum toxin solutions to include: how religion and belief can prohibit a botulinum toxin type A procedure |
KU6 | ||
| 1.3 | Explain the physiological effect botulinum toxin type A solution has on the targeted and surrounding facial muscle structures to include:
• adaptation of injection techniques • adaptation of depth and placement |
KU7 | ||
| 1.5 | Explain the purpose, use and limitations of botulinum toxin type A procedures in relation to:
• past and current medical history • previous non-surgical cosmetic and/or dental procedure history • relevant lifestyle factors • contraindicated medication and medical conditions • the client’s physical and psychological suitability for the non-surgical cosmetic procedure • client expectations |
KU8
|
||
| 1.6 | Explain t he regulatory and legislative requirements for prescription-only medicines to include licensed and offlabel product use | KU12 | ||
| 1.7 | Explain the licensed indicated use of prescription-only medicines and when and why they can be used off-label considering:
• safety • treatment area • suitability • agreement with the regulated independent prescriber
|
KU13 | ||
| 1.8 | Explain the legislative requirements and restrictions for sourcing, storing and using licensed topical anaesthetics | KU15 | ||
| 1.9 | Describe the health and safety responsibilities in line with legislation before, during and after the botulinum toxin type A procedure | KU16 | ||
| 1.10 | Explain the legislative and indemnity requirements for gaining signed, informed consent for the elective nonsurgical cosmetic procedure
|
KU25 | ||
| 1.11 | Explain the legislative, insurance and organisational requirements for taking and storing visual media of the client’s treatment area | KU30 | ||
| 1.12 | Explain the legislative and regulatory requirements for completing and storing the client’s medical and nonsurgical cosmetic procedure records | KU31 | ||
| LO2 | Conduct a client consultation and develop a personalised procedure plan for botulinum toxin procedures
|
2.1 | Conduct a structured face-to-face client consultation, ensuring compliance with health and safety before, during, and after the botulinum toxin type A procedure, and effectively use visual aids to explain anticipated physical effects | PC3
KU17, KU21, KU32 |
| 2.2 | Discuss client objectives, concerns, expectations and desired outcomes to inform the botulinum toxin type A procedure plan including; fee structure, treatment options, and alternative treatment options | PC4
KU20, KU22 |
||
| 2.3 | Establish the botulinum toxin type A procedure plan in accordance with legislative requirements and organisational policies and procedures | PC5 | ||
| 2.4 | Reiterate, confirm and agree with the client that they have understood the proposed botulinum toxin type A procedure and pain management to including:
• contra-actions • adverse reactions
|
PC6
KU9, KU11 |
||
| 2.5 | Obtain and review the client’s written informed consent for the botulinum toxin type A procedure and pain management, allowing an adequate time scale for the client to make an informed choice digital skin scanner | PC7, PC8
KU14, KU23, KU24 |
||
| 2.6 | Obtain the fulfilled prescription from the pharmacist with the client’s informed consent to include:
• patient-specific direction • saline reconstitution solutions • device and needle type • storage instructions • waste disposal protocol |
PC9 | ||
| LO3 | Deliver botulinum toxin
procedures safely and effectively
|
3.1 |
Select an effective hygiene preparation product to meet the client’s needs in accordance with the manufacturer’s instructions |
PC10,
KU26 |
| 3.2 | Prepare the client’s treatment area in line with botulinum toxin type A protocol and risk management strategies, including marking the procedure sites where applicable | PC11 | ||
| 3.3 | Inject the botulinum toxin type A solution with a sterile, single-use needle following the botulinum toxin type A procedure protocol to include:
• adaptation of injection techniques, depth and placement • in accordance with the preprocedure markings if applicable |
PC12,
KU27 |
||
| 3.4 | Monitor the client’s health, wellbeing and skin response throughout the botulinum toxin type A procedure, ensuring compliance with legislative requirements and organisational policies and procedures | PC13
KU28 |
||
| 3.5 | In the event of an adverse reaction or incident, the aesthetic practitioner must take prompt corrective action following the emergency plan to include:
promptly obtain medical intervention from the designated healthcare professional when complications arise and |
PC14
KU9, KU10, KU29 |
||
| prescription-only medicine is required | ||||
| 3.6 | Conclude the procedure in line with the botulinum toxin type A protocol, legislative requirements and organisational procedures to include:
removing any pre-procedure markings if applicable |
PC15 | ||
| 3.7 | Capture and securely store clientapproved images of the procedure area in compliance with insurance and organisation requirements | PC16 | ||
| 3.8 | Complete the client’s non-surgical cosmetic procedure records and store in line with data legislation | PC17 | ||
| LO4 | Provide aftercare for botulinum toxin procedures and review procedure outcomes
|
4.1 | Provide verbal and written instructions and confirm the client’s receipt of pre and post-procedure advice to include:
• the regulated independent prescriber’s contact details • emergency plan • contingency plan in the event of absence |
PC19
KU36 |
| 4.2 | Discuss the outcomes and agree future procedures with the client | PC21 | ||
| 4.3 | Discuss, evaluate and record the outcomes with the regulated independent prescriber and agree further action and future procedures | PC20
KU34, KU35 |
||
| LO5 | Reflect on practice and engage in continuing professional development
|
5.1 | Keep a reflective journal, review the botulinum toxin procedure and evaluate own strengths and areas for improvement | PC18,
KU33 |
| 5.2 | Explain the importance in engaging in, and documenting continuous professional development including keeping updated on policies, procedures and best practice guidance | KU4 | ||
Need Help With Your AP707 Clinical Aesthetic Procedures (Y/651/9196) Assignment?
The post AP707 Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face (Y/651/9196) Assignment Brief 2026 appeared first on Students Assignment Help UK.